Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.

Pilar Garrido, Ulrik Lassen, Hendrik‐Tobias Arkenau et al.|Journal of Clinical Oncology|2014

Cited by 4